Recombinant 2019-nCoV S1+S2 ECD (S-ECD) Protein with His tag

The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates thisinteraction.The S protein plays key parts in the induction of neutralizing-antibody and T-cellresponses, as well as protective immunity.
Recombinant SARS-COV-2 S1+S2 ECD (S-ECD) Protein with His tag (Wild type, pre-fusion state plus post-fusion state) is produced by HEK293 cells expression system. The target protein is expressed with sequence (Val11-Gln1208) of SARS-COV-2(2019-nCoV) S1+S2 ECD (S-ECD) (Accession #YP_009724390.1) fused with a 6XHis tag at the C-terminus.

Measured by its binding ability in a functional ELISA. Immobilized Recombinant SARS-COV-2 Spike S1+S2 ECD-His at 2μg/mL (100 μL/well) can bind Recombinant Human ACE2 with a linear range of 0.15-9.92 ng/mL.

This product is stable at ≤ -70°C for up to 6 months from the date of receipt. For optimal storage, aliquot into smaller quantities after centrifugation and store at recommended temperature. Avoid repeated freeze-thaw cycles.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Data presented is the available current product information and provided as-is. These products have not been tested or verified in any additional applications, sample types, including any clinical use. Experimental conditions must be empirically derived by the user. Our Antibody Guarantee only covers tested applications stated herein and conditions presented in our product information and is not extended to publications.